培美曲塞联合顺铂二线治疗晚期肺腺癌的研究

Pemetrexed Plus Cisplatin Second-line Treatment of Advanced Lung Adenocarcinoma

目的探讨培美曲塞联合顺铂二线治疗晚期肺腺癌的疗效。方法 60例一线吉非替尼治疗失败的晚期肺腺癌患者作为研究对象,使用培美曲塞联合顺铂进行治疗。每2个治疗周期后对疗效以及安全性、不良反应等进行评价。结果治疗有效率为33.33%,疾病控制率为71.66%。治疗中主要不良反应对后续化疗无影响,均可耐受,未出现化疗相关性死亡。结论培美曲塞联合顺铂二线治疗晚期肺腺癌疗效明显,毒副作用较轻且可耐受,具有临床推广价值。

Objective To investigate the efficacy of pemetrexed in combination with cisplatin regimen as second-line therapy for patients with advanced lung adenocareinoma. Methods 60 patients failed in the first-line treatment using gefitinib with advanced lung adenoearcinoma as the object of study, all the patient received pemetrexed combined with cisplatin regimen. After every two cycles of treatment, evaluation for the efficacy and safety, adverse were be taken. Results The RR was 33.33%, DCR was 71.66%. Major adverse events in treatment had no effects on subsequent chemotherapy and all patients could tolerate with no chemothera- py-related deaths. Conclusion Therapy of pemetrexed combined with cisplatin for advanced lung adenoearcinoma has better effi- cacy, slighter toxicity and more tolerance. That is more suitable for clinical use.